enVio
Seattle Genetics’ prospective $2 billion licensing deal not without controversy
February 13, 2017Sales and Marketing Immunomedics, Seattle Genetics, enVio
Immunomedics announced on 10 February that it had entered a licensing agreement with Seattle Genetics for its leading experimental cancer …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
